GO
Loading...

Takeover Bids

More

  • *Pfizer works on next move in takeover bid for Astrazeneca. *U.S. drugmaker Pfizer Inc is working on its next move in a potential $100 billion bid to take over Britain's AstraZeneca Plc after having two bids rejected.

  • UPDATE 1-Meda board rejects new Mylan offer Monday, 28 Apr 2014 | 2:50 AM ET

    STOCKHOLM, April 28- Swedish drugmaker Meda has rejected an improved takeover offer from U.S. generics firm Mylan, saying it was confident in its future as an independent company and its biggest shareholder did not support the bid.

  • PARIS/ NEW YORK, April 24- Alstom said on Thursday it was not informed of any potential public tender offer for its shares, which opened 17 percent higher after Bloomberg reported that General Electric was in talks to buy the French turbine and train maker for about $13 billion.

  • Hedge fund & big pharma pair up     Wednesday, 23 Apr 2014 | 1:32 PM ET

    CNBC's Dominic Chu provides a timeline of Bill Ackman's stake in Allergan.

  • Carl Icahn's take on Ackman & Valeant     Wednesday, 23 Apr 2014 | 9:19 AM ET

    Activist investor Carl Icahn comments on Bill Ackman's role in the Valeant Pharmaceuticals bid for Allergan. The "Squawk on the Street" team provide insight.

  • Cramer: Can't lose if you're Ackman     Wednesday, 23 Apr 2014 | 9:17 AM ET

    The "Squawk on the Street" news team discuss the involvement of Bill Ackman in the deal between Valeant Pharmaceuticals and Allergan.

  • William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.

  • Ackman: Allergan clear fit for Valeant     Wednesday, 23 Apr 2014 | 7:41 AM ET

    William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.

  • J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.

  • Valeant CEO: Allergan has a great set of assets     Wednesday, 23 Apr 2014 | 7:33 AM ET

    J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.

  • Ackman: Valeant fit into Pershing investing mold     Wednesday, 23 Apr 2014 | 7:32 AM ET

    William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.

  • Einhorn's new course     Tuesday, 22 Apr 2014 | 2:31 PM ET

    Sandy Villere, Villere Funds, shares his thoughts on Greenlight Capital's new stake in Conn's.

  • Pharma deal frenzy     Tuesday, 22 Apr 2014 | 10:01 AM ET

    CNBC's Meg Tirrell digs into the friendly and hostile M&A action taking place in pharmaceuticals, including a deal between Novartis and GlaxoSmithKline, and Valeant Pharmaceuticals bid for Allergan.

  • Valeant's offer for Allergan     Tuesday, 22 Apr 2014 | 8:03 AM ET

    Valeant Pharmaceuticals offered $48.30 share cash, as well as 0.83 shares for Allergan. CNBC's Meg Tirrell provides insight.

  • Ackman & Valeant's bid for Allergan     Tuesday, 22 Apr 2014 | 7:04 AM ET

    In an SEC Filing, Valeant Pharmaceuticals said it expected to offer a mix of stock and about $15 billion in cash for botox maker Allergan. David Krempa, Morningstar equity analyst, and CNBC's Meg Tirrell, provide perspective.

  • *Rejects shareholder Vintage Capital's $2.3 bln offer. April 15- Aaron's Inc, a rent-to-own furniture and electronics retailer, rejected a $2.3 billion takeover offer from a major shareholder and instead bought a web-based retail credit financing firm for about $700 million to provide customers with easier payment terms.

  • April 15- Hedge fund Elliott Management reaffirmed its $3.36 billion offer for network gear maker Riverbed Technology Inc after being rebuffed twice, saying it remained "extremely interested" in acquiring the company. The stock had touched a high of $22.76 in February after Elliot raised its initial bid by $2 to $21 per share.

  • April 15- Hedge fund Elliott Management reaffirmed its $3.36 billion offer for network gear maker Riverbed Technology Inc, saying it remained "extremely interested" in acquiring the company. Riverbed rejected Elliott Management's raised bid in February, saying the offer undervalued the company.

  • April 15- Aaron's Inc, a rent-to-own furniture and electronics retailer, rejected a $2.3 billion takeover offer from a major shareholder and instead acquired a retail credit financing firm for about $700 million.

  • JGBs little changed, 5-yr auction draws solid bids Tuesday, 15 Apr 2014 | 1:12 AM ET

    TOKYO, April 15- Japanese government bond prices were little changed on Tuesday, erasing small earlier losses after an auction of five-year JGBs drew solid bids. The 10- year JGB futures ticked up 0.04 point to 145.09, coming back from the day's low of 144.99.